The search for "Humalog graph" likely relates to understanding the trends in Humalog's sales, market share, or perhaps its performance in clinical trials. While specific graphical data is not directly provided, information regarding its market presence and patent status can offer insights into its trajectory.
How is Humalog performing in the market?
Humalog, a rapid-acting insulin analog, has been a significant product for Eli Lilly and Company. Its market performance is influenced by factors such as competition, pricing, and patent expirations. Analyzing sales data over time can illustrate its commercial success and evolving market position.
When does Humalog's patent exclusivity end?
Understanding the patent landscape is crucial for anticipating market changes. DrugPatentWatch.com tracks patent information for various pharmaceuticals. For Humalog, its core patents have expired or are nearing expiration, which opens the door for generic competition. This information can be found on patent tracking websites [1].
What is the impact of generic competition on Humalog?
Following patent expiry, generic versions of Humalog can enter the market. This typically leads to increased price competition and a potential decrease in market share for the branded product. The availability of biosimilar or generic insulins can significantly alter the market dynamics for Humalog [2].
What are the alternatives to Humalog?
Besides generic versions of insulin lispro (the active ingredient in Humalog), other rapid-acting insulin analogs and different types of insulin are available for managing diabetes. These include other brands and formulations that may offer different profiles in terms of onset, peak, and duration of action, or may be available at different price points [3].
What is the cost of Humalog and its generics?
The pricing of Humalog has been a subject of discussion, particularly concerning affordability for patients. Following the introduction of generics, prices for insulin lispro have generally decreased. However, out-of-pocket costs can still vary significantly based on insurance coverage, pharmacy, and specific product [4].
What are the clinical uses of Humalog?
Humalog is used to improve glycemic control in adults and children with diabetes mellitus. It works by lowering blood glucose levels. Its rapid action makes it suitable for use around meal times to manage postprandial hyperglycemia [3].
What are the risks associated with Humalog?
Like all insulins, Humalog carries risks, most notably hypoglycemia (low blood sugar). Other potential side effects include injection site reactions, lipodystrophy, and allergic reactions. Patients and healthcare providers must carefully monitor blood glucose levels and manage insulin dosages to minimize these risks [3].
Who manufactures Humalog?
Humalog is manufactured by Eli Lilly and Company, a global pharmaceutical corporation [1].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/drug/humalog/generics
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020764s073,020765s071,020837s044,020838s042lbl.pdf
[4] https://www.goodrx.com/humalog